"Patients consider pruritus one of the most important and troublesome symptoms of psoriasis, affecting their daily activities and emotional wellbeing,” said Dr David Pariser (Pariser Dermatology Specialists Virginia, USA) during his presentation of the trial. At present, treatments for psoriasis do not consistently alleviate associated pruritus. Serlopitant is an oral, once daily neurokinin-1 receptor antagonist that demonstrated significant reduction in pruritus in phase 2 studies in patients with chronic pruritus and prurigo nodularis [2]. In the present trial, the agent was assessed in patients with psoriasis and worst itch according to an NRS (WI-NRS) at baseline (score ≥ 7) [3]. Primary endpoint was the WI-NRS 4-point responder rate at week 8, and the secondary endpoint was the WI-NRS 4-point responder rate at week 4.
At week 8, 33.3% of patients treated with serlopitant had a response compared with 21.1% in the placebo arm (P=0.028). The corresponding rates at week 4 were 20.8% for serlopitant vs 11.5% for placebo (P=0.039). Treatment was also well tolerated with no serious adverse events reported for serlopitant and TEAEs occurred with similar frequency in both groups. “As therapy with serlopitant resulted in a clinically meaningful improvement of pruritus associated with psoriasis, we plan a phase 3 study of serlopitant for this indication,” concluded Dr Pariser.
1. Szepietowski JC, Reich A. Eur J Pain 2016;20:41-6.
2. Yosipovitch G, et al. J Am Acad Dermatol 2018;78:882-91.
3. Spellman M. Abstract 11417, AAD Annual Meeting, 1-5 March 2019, Washington DC, USA.
Posted on
Previous Article
« Hair Loss: No Reason for Therapeutic Nihilism Next Article
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma »
« Hair Loss: No Reason for Therapeutic Nihilism Next Article
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma »
Table of Contents: AAD 2019
Featured articles
Letter from the Editor
Interview with AAD president Prof. George J. Hruza
Late-Breakers
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab – a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
Atopic Dermatitis: Many New Therapies in the Pipeline
New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
What's New and Hot in Acne
Should we use more hormonal therapy?
Pearls of the Posters
Pemphigus patients prone to osteoporosis
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma
Related Articles
November 26, 2019
Long-term data from CheckMate 067
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com